SEARCH

SEARCH BY CITATION

References

  • 1
    Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295301.
  • 2
    Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347356.
  • 3
    Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312323.
  • 4
    Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).. Hepatology 1999; 30: 238243.
  • 5
    Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101109.
  • 6
    Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756763.
  • 7
    Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629634.
  • 8
    Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow up of patients with chronic hepatitis B treated with interferon-alfa. Gastroenterology 1997; 113: 16601667.
  • 9
    van Zonneveld M, Honkoop P, Hansen BE, Niesters HGM, Murad SD, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804810.
  • 10
    Cooksley WGE, Piratvisuth T, Lee S-D, Mahachai V, Chao Y-C, Tanwandee T, et al. Peginterferon α-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatitis 2003; 10: 298305.
  • 11
    Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 266272.
  • 12
    van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 14211425.
  • 13
    Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B: a two-year study. J Hepatol 2005; 43: 6066.
  • 14
    Lok AS, McMahon BJ. AASLD Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic Hepatitis B:update of recommendations. Hepatology 2004; 39: 857861.
  • 15
    Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific Consensus Update Working Party on Chronic Hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472489.
  • 16
    The EASL Jury. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002, Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38: 533540.
  • 17
    Perrillo RP, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908916.
  • 18
    van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420424.
  • 19
    Perrillo RP. Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin Liver Dis 2004; 24( Suppl 1): 2329.
  • 20
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al., on behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 15271532.
  • 21
    Marcellin P, Chang T, Lim S, Sievert W, Tong M, Arterburn S, et al. Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients [Abstract]. J Hepatol 2005; 42( Suppl 2): 31.
  • 22
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang T-T, Kitis G, Rizzetto M, et al. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 26732681.
  • 23
    Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [Abstract]. J Hepatol 2005; 42:( Suppl 2): 17.
  • 24
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 15211531.
  • 25
    Keeffe EB, Dieterich DT, Han S-H B, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87106.
  • 26
    Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003; 23: 8188.
  • 27
    Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 1992; 1034: 16491656.
  • 28
    Fong TL, DiBisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993; 18: 13131318.
  • 29
    Werle-Lapostolle, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 17501758.
  • 30
    Komori M, Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, et al. Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. J Hepatol 2001 35: 798804.
  • 31
    Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 16681674.
  • 32
    Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma H, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494499.
  • 33
    Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation 1995; 59: 230234.
  • 34
    Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Crax A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102110.
  • 35
    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 11041108.
  • 36
    Ferrari C, Missale G, Boni C, Urbani S. Immunopathogenesis of hepatitis B. J Hepatol 2003; 39( Suppl): S36S42.
  • 37
    Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. European Concerted Action on Viral Hepatitis (EUROHEP): delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998: 93: 896900.
    Direct Link:
  • 38
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991; 100: 182188.
  • 39
    Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the 2 in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 12061217.
  • 40
    Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123129.
  • 41
    Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. PEGinterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 26822695.
  • 42
    Yuen MF, Wong DK, Yuan HJ, Sum SM, Lai CL. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. J Clin Microbiol 2004; 42: 48824884.
  • 43
    Sung JJ, Wong M-L, Bowden S, Liew C-T, Hui AY, Wong VWS, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 18901897.
  • 44
    Kock J, Baumert TF, Delaney WE IV, Blum HE, von Weizsacker F. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupia hepatocytes. Hepatology 2003; 38: 14101418.
  • 45
    Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 2004; 15: 299305.
  • 46
    Perrillo RP. Interferon in the management of chronic hepatitis B. Dig Dis Sci. 1993; 38: 577593.
  • 47
    Xiong W, Wang X, Liu XY, Xiang L, Zheng LJ, Liu JX, et al. Analysis of gene expression in hepatitis B virus transfected cell line induced by interferon. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003; 35: 10531060.
  • 48
    Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968975.
  • 49
    Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996; 24: 991995.
  • 50
    Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 14221427.
  • 51
    Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26: 13381342.
  • 52
    Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748755.
  • 53
    Ryu SH, Chung Y-H, Choi MH, Kim JA, Shin JW, Jang MK, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003; 39: 614619.
  • 54
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803806.
  • 55
    Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepatol 2004; 11: 432438.
  • 56
    Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121129.
  • 57
    Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 10391047.
  • 58
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127( Suppl 1): S35S50.
  • 59
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168174.
  • 60
    Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265272.
  • 61
    Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 17141722.
  • 62
    Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172180.
  • 63
    Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105117.
  • 64
    Perrillo R, Hann H-W, Mutimer D, Willems B, Leung N, Lee WM. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 8190.
  • 65
    Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 66
    Chang T-T, Hadziyannis S, Cianciara J, Rizzetto M, Schiff E, Pastore G, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine [Abstract]. Hepatology 2002; 36( Suppl): 300A.
  • 67
    Someya T, Suzuki Y, Arase Y, Kobayashi M, Suzuki F, Tsubota A, et al. Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant. J Gastroenterol 2001; 36: 133136.
  • 68
    Colonno R, Rose RE, Levine SM, Pokornowski K, Plym M, Yu CF, et al. Entecavir (ETV) resistance is not observed in nucleoside-naïve subjects and is observed infrequently by week 48 in lamivudine-refractory subjects with chronic HBV infection [Abstract]. J Hepatol 2005; 42( Suppl 2): 173.
  • 69
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292297.
  • 70
    Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 13911398.
  • 71
    Qi X, Zhu Y, Curtis M, Yang H, Currie G, Miller MD, et al. In vitro cross-resistance analysis of the HBV polymerase mutation A181V [Abstract]. J Hepatol 2005; 42( Suppl 2): 194.
  • 72
    Thomas HC, Karayiannis P, Brook G. Treatment of hepatitis B virus infection with interferon: factors predicting response to interferon. J Hepatol 1991; 13( Suppl 1): S4S7.
  • 73
    Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, DiBisceglie A, et al. Randomized, controlled trial of recombinant alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 13181325.
  • 74
    DiMartino V, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123: 18121822.
  • 75
    Cooksley G, Lau GKK, Liaw Y-F, Marcellin P, Chow WC, Thongsawat S, et al. Effect of genotype and other baseline factors on response to PEGInterferon α-2a (40kDa) (Pegasys®) in HBeAg-positive chronic hepatitis B: results from a large, randomized study [Abstract]. J Hepatol 2005; 42( Suppl 2): S30.
  • 76
    Bonino F, Lau G, Marcellin P, Hadziyannis S, Kitis G, Papanikolau G, et al. The first detailed analysis of predictors of response in HbeAg-negative chronic hepatitis B: data from a multicenter, randomized, partially double-blind study of peginterferon alfa-2a (40 kD) (Pegasys®) alone or in combination with lamivudine vs lamivudine alone [Abstract]. Hepatology 2004; 40( Suppl 1): 659A.
  • 77
    Farci P, Marcellin P, Lu Z-M, Diago M, Lai M-Y, Gurel S, et al. On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with PEGInterferon α-2a (40 kDa) (Pegasys®) [Abstract]. J Hepatol 2005; 42( Suppl 2): S175.
  • 78
    Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 9981002.
  • 79
    Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716725.
  • 80
    Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002; 36: 14251430.
  • 81
    Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 10091013.
  • 82
    Janssen HL, Flink HJ, van Zonneveld M, Niesters HG, de Man RA, Schalm SW. HBsAg seroconversion in chronic HBV patients treated with pegylated interferon alpha-2b alone or in combination with lamivudine: the role of HBV genotype [Abstract]. Hepatology 2004; 40: 660A.
  • 83
    Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SE, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186194.
  • 84
    Lok AS, Schiff ER, Tsai NC, Rustgi VK, Shiffman M, Martin P, et al. Entecavir is effective irrespective of baseline ALT and HBV DNA strata for histological and virological endpoints [Abstract]. Gastroenterology 2005; 128( Suppl 2): A742.
  • 85
    Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687696.
  • 86
    Westland C, Delaney W IV, Yang H, Chen SS, Marcellin P, Hadziyannis S, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003; 125: 107116.
  • 87
    Lurie Y, Manns MP, Gish RG, Chang TT, Lai CL, Shouval D, et al. The efficacy of entecavir is similar regardless of disease-related baseline subgroups in the treatment of nucleoside-naïve, HBeAg (+) amd HBeAg (-) patients with chronic hepatitis B [Abstract]. J Hepatol 2005; 42( Suppl 2): S184.
  • 88
    Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22: 18631873.
  • 89
    Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664675.
  • 90
    Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am J Manag Care 2001; 7: 677682.
  • 91
    Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17: 409427.
  • 92
    Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BMR. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 821831.
  • 93
    Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 115.
  • 94
    Brunelle MN, Jacquard AC, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Susceptibility to antivirals of an HBV strain harboring polymerase mutations conferring resistance to both lamivudine and adefovir [Abstract]. Hepatology 2004; 40( Suppl): 265A.
  • 95
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation. The Lamivudine North American Transplant Group. Hepatology 2001; 33: 424432.
  • 96
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. PEG interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 16661672.
  • 97
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 98
    Van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepatitis 2003; 10: 294297.
  • 99
    Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: a multicentre, randomised, double-blind, placebo-controlled study [Abstract]. Hepatology 2004; 40( Suppl 1): 272A.
  • 100
    Schmilovitz-Weiss H, Ben Ari Z, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2005; 24: 547551.